BMY Q2 2020 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q2 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$10.1B+61.5% YoY

Gross Profit

$5.0B49.8% margin

Operating Income

$939M9.3% margin

Net Income

-$85M-0.8% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

$4.5B

Free Cash Flow

$4.4B

Stock-Based Comp.

$213M

Balance Sheet

Total Assets

$128.1B

Total Liabilities

$78.9B

Stockholders' Equity

$49.1B

Cash & Equivalents

$19.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10.1B	$6.3B	+61.5%
Gross Profit	$5.0B	$4.4B	+14.7%
Operating Income	$939M	$2.0B	-53.5%
Net Income	-$85M	$1.4B	-105.9%

Revenue Segments

Revlimid

$2.9B29%

Eliquis

$2.2B22%

Opdivo

$1.7B17%

Orencia

$750M8%

Pomalyst/Imnovid

$745M7%

Sprycel

$511M5%

Yervoy

$369M4%

Mature Products And All Other

$331M3%

Abraxane

$308M3%

Baraclude

$121M1%

Empliciti

$97M1%

Reblozyl

$55M1%

Zeposia

$1M0%

Geographic Segments

UNITED STATES

$6.5B64%

Europe

$2.1B21%

Rest Of World

$1.3B13%

Other Region

$172M2%